Liquidia Corp (LQDA)
12.79
-0.19
(-1.46%)
USD |
NASDAQ |
May 03, 16:00
12.78
0.00 (0.00%)
After-Hours: 20:00
Liquidia Enterprise Value: 893.26M for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 893.26M |
| May 02, 2024 | 907.77M |
| May 01, 2024 | 922.28M |
| April 30, 2024 | 897.84M |
| April 29, 2024 | 868.43M |
| April 26, 2024 | 873.40M |
| April 25, 2024 | 856.78M |
| April 24, 2024 | 870.47M |
| April 23, 2024 | 900.88M |
| April 22, 2024 | 918.37M |
| April 19, 2024 | 926.73M |
| April 18, 2024 | 966.26M |
| April 17, 2024 | 970.07M |
| April 16, 2024 | 948.78M |
| April 15, 2024 | 956.38M |
| April 12, 2024 | 976.91M |
| April 11, 2024 | 1.082B |
| April 10, 2024 | 1.044B |
| April 09, 2024 | 1.054B |
| April 08, 2024 | 1.067B |
| April 05, 2024 | 1.111B |
| April 04, 2024 | 1.080B |
| April 03, 2024 | 1.083B |
| April 02, 2024 | 1.086B |
| April 01, 2024 | 1.051B |
| Date | Value |
|---|---|
| March 28, 2024 | 1.038B |
| March 27, 2024 | 1.062B |
| March 26, 2024 | 1.127B |
| March 25, 2024 | 1.108B |
| March 22, 2024 | 1.188B |
| March 21, 2024 | 1.151B |
| March 20, 2024 | 1.125B |
| March 19, 2024 | 1.135B |
| March 18, 2024 | 1.099B |
| March 15, 2024 | 1.125B |
| March 14, 2024 | 1.081B |
| March 13, 2024 | 1.036B |
| March 12, 2024 | 979.19M |
| March 11, 2024 | 951.06M |
| March 08, 2024 | 980.72M |
| March 07, 2024 | 951.91M |
| March 06, 2024 | 949.64M |
| March 05, 2024 | 961.77M |
| March 04, 2024 | 954.19M |
| March 01, 2024 | 1.017B |
| February 29, 2024 | 989.82M |
| February 28, 2024 | 1.007B |
| February 27, 2024 | 1.030B |
| February 26, 2024 | 1.025B |
| February 23, 2024 | 1.002B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
25.06M
Minimum
Sep 03 2019
1.188B
Maximum
Mar 22 2024
258.09M
Average
205.13M
Median
Dec 30 2021
Enterprise Value Benchmarks
| United Therapeutics Corp | 9.534B |
| AIM ImmunoTech Inc | 7.819M |
| Perspective Therapeutics Inc | 1.055B |
| Protalix BioTherapeutics Inc | 58.97M |
| Armata Pharmaceuticals Inc | 158.79M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -27.45M |
| Revenue (Quarterly) | 4.531M |
| Total Expenses (Quarterly) | 30.97M |
| EPS Diluted (Quarterly) | -0.42 |
| Gross Profit Margin (Quarterly) | 78.08% |
| Profit Margin (Quarterly) | -605.8% |
| Earnings Yield | -9.38% |
| Normalized Earnings Yield | -9.103 |